Stock Research for FATE


Featured Broker: Ally Invest

Get the due diligence for another stock.


FATE Stock Chart & Research Data

The FATE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the FATE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


FATE Due diligence Resources & Stock Charts

The FATE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View FATE Detailed Price Forecast - CNN Money CNN View FATE Detailed Summary - Google Finance
Yahoo View FATE Detailed Summary - Yahoo! Finance Zacks View FATE Stock Research & Analysis -

Stock Analysis

TradeIdeas View FATE Trends & Analysis - Trade-Ideas Barrons View FATE Major Holders - Barrons
NASDAQ View FATE Call Transcripts - NASDAQ Seeking View FATE Breaking News & Analysis - Seeking Alpha
Spotlight View FATE Annual Report - OTC Report View FATE OTC Short Report -
TradeKing View FATE Fundamentals - TradeKing Charts View FATE SEC Filings - Bar Chart
WSJ View Historical Prices for FATE - The WSJ Morningstar View Performance/Total Return for FATE - Morningstar
MarketWatch View the Analyst Estimates for FATE - MarketWatch CNBC View the Earnings History for FATE - CNBC
StockMarketWatch View the FATE Earnings - StockMarketWatch MacroAxis View FATE Buy or Sell Recommendations - MacroAxis
Bullish View the FATE Bullish Patterns - American Bulls Short Pains View FATE Short Pain Metrics -

Social Media Mentions

StockTwits View FATE Stock Mentions - StockTwits PennyStocks View FATE Stock Mentions - PennyStockTweets
Twitter View FATE Stock Mentions - Twitter Invest Hub View FATE Investment Forum News - Investor Hub
Yahoo View FATE Stock Mentions - Yahoo! Message Board Seeking Alpha View FATE Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for FATE - Insider Cow View Insider Transactions for FATE - Insider Cow
CNBC View FATE Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for FATE - OTC Markets
Yahoo View Insider Transactions for FATE - Yahoo! Finance NASDAQ View Institutional Holdings for FATE - NASDAQ

Stock Charts

FinViz View FATE Stock Insight & Charts - StockCharts View FATE Investment Charts -
BarChart View FATE Stock Overview & Charts - BarChart Trading View View FATE User Generated Charts - Trading View

Latest Financial News for FATE

Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting
Posted on Tuesday December 04, 2018

Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced new preclinical data on the Company’s induced pluripotent stem cell (iPSC) product platform and its iPSC-derived, off-the-shelf cell-based cancer immunotherapy pipeline at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition. Last week, the Company announced that the U.S. Food and Drug Administration (FDA) allowed its Investigational New Drug (IND) Application for FT500, the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master iPSC line.

Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products
Posted on Monday December 03, 2018

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has secured an exclusive option to an intellectual property portfolio owned by the Max Delbrück Center for Molecular Medicine (MDC) covering novel humanized chimeric antigen receptor (CAR) constructs that uniquely and specifically bind B-cell Maturation Antigen (BCMA). Under the agreement with MDC, Fate Therapeutics holds an exclusive option to exclusively license the portfolio for all cell products, including CAR NK- and T-cell products, derived from induced pluripotent stem cells (iPSCs).

Fate Therapeutics (FATE) Jumps: Stock Rises 8.9%
Posted on Monday December 03, 2018

Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence
Posted on Monday December 03, 2018

NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.